리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 11월
페이지 정보:영문 179 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 세포 생존율 어세이 시장은 2030년까지 83억 달러에 달할 전망
2024년에 55억 달러로 추정되는 세계의 세포 생존율 어세이 시장은 2024-2030년의 분석 기간에 CAGR 7.1%로 성장하며, 2030년까지 83억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석 대상 부문의 하나인 소모품 컴포넌트는 7.8%의 CAGR을 기록하며, 분석 기간 종료까지 53억 달러에 달할 것으로 예측됩니다. 기기 컴포넌트 부문의 성장률은 분석 기간에 6.0%의 CAGR로 추정되고 있습니다.
미국 시장은 15억 달러로 추정되는 한편, 중국은 6.6%의 CAGR로 성장할 것으로 예측됩니다.
미국의 세포 생존율 어세이 시장은 2024년에 15억 달러로 추정되고 있습니다. 세계 2위의 경제대국인 중국은 2024-2030년의 분석 기간에 CAGR 6.6%로 추이하며, 2030년까지 13억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역 시장으로는 일본과 캐나다를 들 수 있으며, 분석 기간에 각각 6.6%, 5.7%의 CAGR로 성장할 것으로 예측됩니다. 유럽에서는 독일이 약 5.8%의 CAGR로 성장할 것으로 전망되고 있습니다.
세계의 세포 생존율 어세이 시장 - 주요 동향과 촉진요인 요약
세포 생존율 분석이 생의학 연구를 어떻게 변화시키고 있는가?
세포 생존율 분석은 다양한 실험 조건에서 세포의 건강 상태와 대사 활성을 평가하기 위한 필수 툴로서 생의학 연구의 기반이 되고 있습니다. 이러한 분석은 세포의 생사 판단뿐만 아니라 증식, 분열, 자극 반응 능력의 모니터링에도 사용되며, 암 연구, 신약개발, 독성학 등의 분야에서 매우 중요합니다. 세포 생존율 분석은 화합물이 세포 생존에 미치는 영향을 측정함으로써 신약 후보물질의 효능을 평가하는 데 매우 중요하며, 특히 수백 개의 화합물을 동시에 테스트하는 하이스루풋 스크리닝 프로그램에서 매우 중요합니다. 암 연구에서는 약물 노출 후 암세포의 생존 및 증식 능력을 판단하여 치료법의 유효성 평가에 기여합니다. 세포 생존율 분석에서 얻은 데이터는 치료제 개발의 의사결정을 유도하고 다양한 치료제의 세포 수준 작용기전을 이해하는 데 매우 유용합니다. 분석 기술과 검출 방법의 발전으로 세포 생존율 분석은 더욱 민감하고 다용도해져 학술연구와 의약품 개발 모두에 필수적인 요소로 자리 잡았습니다.
세포 생존율 분석이 신약 개발 및 독성학에서 중요한 이유
세포 생존율 분석은 다양한 화합물이 세포의 건강 상태와 대사에 미치는 영향에 대한 중요한 정보를 제공하므로 신약개발과 독성학에서 필수적인 역할을 하고 있습니다. 신약개발에서는 암세포 등 병변세포의 증식을 억제하면서 정상세포에는 영향을 미치지 않는 화합물을 찾아내는 것이 목표입니다. 생존율 분석을 통해 화합물이 세포 생존을 촉진하거나 억제하는 정도를 정량적으로 평가할 수 있으며, 약물의 치료 가능성을 조기에 시사하는 지표가 될 수 있습니다. 이러한 분석은 대규모 화합물 라이브러리의 초기 스크리닝부터 전임상시험의 상세 분석에 이르기까지 의약품 개발의 다양한 단계에서 사용됩니다. 독성학에서도 세포 생존율 분석은 새로운 화학물질, 의약품, 환경 독성 물질이 세포에 미치는 잠재적 유해성을 평가하는 데 있으며, 중요한 역할을 합니다. 이는 새로운 치료제나 소비재가 시장에 출시되기 전에 안전성을 확보하는 데 필수적입니다. 세포가 다양한 농도의 화합물에 어떻게 반응하는지를 테스트함으로써 연구자들은 독성학적 프로파일을 예측하고 잠재적인 부작용을 파악할 수 있습니다. 따라서 세포 생존율 분석은 화합물의 효능과 독성의 균형을 평가하고 보다 안전하고 효과적인 치료법 개발을 유도하는 데 필수적인 툴이 되고 있습니다.
기술 발전은 세포 생존율 분석의 정확도를 어떻게 향상시키고 있는가?
기술 혁신을 통해 세포 생존율 분석의 정확도, 민감도, 속도가 크게 향상되어 다양한 용도에 대한 적응성이 향상되었습니다. 가장 중요한 발전 중 하나는 발광 및 형광 기반 분석의 도입입니다. 이들은 생존 세포를 매우 민감하고 정확하게 검출합니다. 이러한 기술을 통해 세포에 손상을 입히지 않고 실시간으로 건강 상태를 모니터링할 수 있으며, 연구자들은 시간이 지남에 따라 세포 생존율을 지속적으로 평가할 수 있게 되었습니다. 하이스루풋 스크리닝 플랫폼의 활용으로 이러한 분석의 효율성은 더욱 향상되었으며, 실험실에서는 자동화 시스템을 통해 수천 개의 화합물을 병렬로 분석할 수 있게 되었습니다. 마이크로플루이딕스 기술 또한 분석 포맷의 소형화, 시약 소비량 감소, 실험 조건의 제어성 향상을 통해 영향을 미치고 있습니다. 또한 생체내 환경을 보다 충실하게 재현하는 3차원 세포배양 모델 개발로 세포 생존율 분석의 적용 범위가 확대되었습니다. 이를 통해 보다 복잡하고 생리학적으로 정확한 시스템에서 세포의 거동을 평가할 수 있게 되었습니다. 이러한 혁신은 세포 생존율 측정의 정확도를 높일 뿐만 아니라, 보다 신뢰할 수 있는 데이터를 제공함으로써 신약개발, 암 치료, 재생의학 연구를 촉진하고 있습니다.
세포 생존율 분석 시장의 성장을 이끄는 요인은 무엇인가?
세포 생존율 분석 시장의 성장은 신약 개발 툴에 대한 수요 증가, 분석 기술의 발전, 암 연구 및 맞춤 의료에 대한 관심 확대 등 여러 요인에 의해 주도되고 있습니다. 주요 촉진요인 중 하나는 신약 후보물질을 선별하는 보다 효율적이고 신뢰할 수 있는 스크리닝 기법의 필요성입니다. 제약사들이 암, 신경퇴행성 질환, 감염성 질환 등 다양한 질환에 대한 치료제 개발을 목표로 하는 가운데, 고처리량, 고감도 생존율 분석에 대한 수요가 증가하고 있습니다. 실시간 및 고처리량 스크리닝 플랫폼의 개발과 같은 기술 혁신으로 인해 이러한 분석은 보다 쉽게 사용할 수 있고 확장성이 높아져 연구 기관과 산업 환경 모두에서 널리 채택되고 있습니다. 시장 성장을 이끄는 또 다른 중요한 요인은 맞춤형 의료의 부상입니다. 맞춤형 의료는 환자 개개인의 세포가 특정 치료에 어떻게 반응하는지를 평가할 수 있는 정밀한 툴을 필요로 합니다. 암 연구에서 세포 생존율 분석은 종양 세포가 다양한 화학요법 및 표적치료에 어떻게 반응하는지 이해하기 위해 필수적이며, 이를 통해 보다 개인화되고 효과적인 치료 계획을 수립할 수 있습니다. 또한 만성질환의 유병률이 증가함에 따라 더 나은 독성 테스트 툴의 필요성이 증가하고 있으며, 이는 세포 생존율 분석에 대한 수요를 더욱 촉진하고 있습니다. 이러한 요인에 더해 생명과학 연구개발 및 바이오의약품 개발에 대한 투자 증가가 더해져 향후 수년간 세포 생존율 분석 시장은 견고한 성장을 보일 것으로 예측됩니다.
부문 :
컴포넌트(소모품, 기기), 최종 사용(제약·바이오테크놀러지 기업, 학술·연구기관, 병원·진단 검사실, 기타 최종 사용)
조사 대상 기업의 예
Abcam PLC
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
BioTek Instruments, Inc.
Biotium, Inc.
Creative Bioarray
Danaher Corporation
GE Healthcare
Merck KgaA
PerkinElmer, Inc.
Promega Corporation
Thermo Fisher Scientific, Inc.
AI 통합
검증된 전문가 컨텐츠와 AI 툴을 통해 시장 및 경쟁 정보 분석 방식을 혁신하고 있습니다.
Global Industry Analysts는 일반적인 LLM이나 산업별 SLM에 대한 쿼리 방식에 의존하는 대신, 전 세계 도메인 전문가들이 엄선한 컨텐츠 리포지토리를 구축했습니다. 여기에는 비디오 전사, 블로그, 검색엔진 조사, 그리고 방대한 양의 기업, 제품/서비스, 시장 데이터가 포함됩니다.
관세 영향 계수
이번 보고서에는 Global Industry Analysts가 예측한 본사 소재지, 생산기지, 수출입(완제품 및 OEM)에 따른 기업의 경쟁력 변화에 따라 지역 시장에 미치는 관세의 영향을 반영했습니다. 이러한 복잡하고 다면적인 시장 현실은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학을 통해 경쟁사들에게 영향을 미칠 것입니다.
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
세계의 기타 지역
제4장 경쟁
KSA
영문 목차
영문목차
Global Cell Viability Assays Market to Reach US$8.3 Billion by 2030
The global market for Cell Viability Assays estimated at US$5.5 Billion in the year 2024, is expected to reach US$8.3 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. Consumables Component, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Instruments Component segment is estimated at 6.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 6.6% CAGR
The Cell Viability Assays market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.6% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.
Global Cell Viability Assays Market - Key Trends and Drivers Summarized
How Are Cell Viability Assays Revolutionizing Biomedical Research?
Cell viability assays have become a cornerstone in biomedical research, providing scientists with essential tools to assess the health and metabolic activity of cells in various experimental conditions. These assays are used to determine whether cells are alive or dead, as well as to monitor their ability to grow, divide, and respond to stimuli, which is crucial in fields like cancer research, drug discovery, and toxicology. Cell viability assays are critical for evaluating the efficacy of new drug candidates by measuring how compounds impact cell survival, especially in high-throughput screening programs where hundreds of compounds are tested simultaneously. In cancer research, these assays help to assess the effectiveness of treatments by determining how well cancer cells can survive and proliferate after drug exposure. The data generated from cell viability assays are invaluable for guiding decisions on therapeutic development and understanding the cellular mechanisms of action behind different treatments. With advancements in assay technologies and detection methods, cell viability assays have become more sensitive and versatile, making them indispensable in both academic research and pharmaceutical development.
Why Are Cell Viability Assays Critical for Drug Discovery and Toxicology?
Cell viability assays are integral to drug discovery and toxicology because they provide key insights into how different compounds affect cellular health and metabolism. In drug discovery, the goal is to identify compounds that can inhibit the growth of diseased cells, such as cancer cells, without affecting healthy cells. Viability assays allow researchers to quantify the extent to which a compound promotes or inhibits cell survival, providing an early indicator of a drug’s therapeutic potential. These assays are used in various stages of drug development, from initial screening of large compound libraries to detailed analysis in preclinical studies. In toxicology, cell viability assays play an equally important role by assessing the potential harmful effects of new chemicals, drugs, or environmental toxins on cells. This is critical for ensuring the safety of new therapeutics and consumer products before they reach the market. By testing how cells respond to different doses of a compound, researchers can predict its toxicological profile and identify potential side effects. This makes cell viability assays indispensable tools for evaluating the balance between a compound’s efficacy and toxicity, guiding the development of safer and more effective treatments.
How Are Technological Advances Enhancing the Precision of Cell Viability Assays?
Technological advancements have greatly improved the precision, sensitivity, and speed of cell viability assays, making them more adaptable to a wide range of applications. One of the most significant developments has been the introduction of luminescence- and fluorescence-based assays, which provide highly sensitive and accurate detection of viable cells. These techniques enable real-time monitoring of cell health without causing damage, allowing researchers to assess cell viability continuously over time. The use of high-throughput screening platforms has further enhanced the efficiency of these assays, enabling laboratories to analyze thousands of compounds in parallel with automated systems. Microfluidics technology has also made an impact by miniaturizing assay formats, reducing reagent consumption, and improving the control over experimental conditions. Moreover, the development of 3D cell culture models, which better mimic the in vivo environment, has expanded the relevance of cell viability assays, as they can now be used to assess cell behavior in more complex, physiologically accurate systems. These innovations are not only enhancing the accuracy of cell viability measurements but are also driving forward research in drug discovery, cancer therapy, and regenerative medicine by providing more reliable data.
What Is Driving Growth in the Cell Viability Assays Market?
The growth in the cell viability assays market is driven by several factors, including the increasing demand for drug discovery tools, advancements in assay technologies, and the expanding focus on cancer research and personalized medicine. One of the major drivers is the need for more efficient and reliable ways to screen new drug candidates. As pharmaceutical companies seek to develop treatments for a wide range of diseases, including cancer, neurodegenerative disorders, and infectious diseases, the demand for high-throughput, sensitive viability assays is increasing. Technological innovations, such as the development of real-time and high-throughput screening platforms, have made these assays more accessible and scalable, contributing to their widespread adoption in both research and industrial settings. Another significant factor driving market growth is the rise of personalized medicine, which requires precise tools to evaluate how individual patient cells respond to specific treatments. In cancer research, cell viability assays are essential for understanding how tumor cells react to various chemotherapies and targeted therapies, allowing for more tailored and effective treatment plans. Additionally, the increasing prevalence of chronic diseases is pushing the need for better toxicity testing tools, further fueling demand for cell viability assays. These factors, along with increased investment in life sciences research and biopharmaceutical development, are expected to drive robust growth in the cell viability assays market in the years ahead.
SCOPE OF STUDY:
The report analyzes the Cell Viability Assays market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Component (Consumables, Instruments); End-Use (Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 11 Featured) -
Abcam PLC
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
BioTek Instruments, Inc.
Biotium, Inc.
Creative Bioarray
Danaher Corporation
GE Healthcare
Merck KgaA
PerkinElmer, Inc.
Promega Corporation
Thermo Fisher Scientific, Inc.
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
Global Economic Update
Cell Viability Assays - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Use of 3D Cell Cultures Throws the Spotlight on Advanced Viability Assay Techniques
Rising Focus on Drug Discovery Propels Growth in Cell Viability Assay Market
Advancements in Fluorescence and Luminescence Assays Strengthen Business Case for Accurate Cell Health Measurement
Rising Prevalence of Chronic Diseases Spurs Growth in Applications of Cell Viability Assays
Innovations in Automated Assay Systems Drive Adoption in Clinical and Research Laboratories
Expanding Stem Cell Research Sustains Growth in the Cell Viability Assay Market
Advances in Live-Cell Imaging Techniques Propel Growth of Real-Time Viability Assays
Growing Use of High-Content Screening in Drug Development Strengthens Demand for Advanced Viability Assay Kits
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Cell Viability Assays Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Cell Viability Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Cell Viability Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Cell Viability Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Hospital & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Hospital & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Hospital & Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Cell Viability Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 23: USA Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 24: USA Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: USA 15-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
TABLE 26: USA Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 27: USA Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: USA 15-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
CANADA
TABLE 29: Canada Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 30: Canada Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: Canada 15-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
TABLE 32: Canada Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: Canada 15-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
JAPAN
Cell Viability Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 35: Japan Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: Japan Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: Japan 15-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
TABLE 38: Japan Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: Japan Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: Japan 15-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
CHINA
Cell Viability Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 41: China Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: China Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: China 15-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
TABLE 44: China Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: China Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: China 15-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
EUROPE
Cell Viability Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 47: Europe Recent Past, Current & Future Analysis for Cell Viability Assays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 48: Europe Historic Review for Cell Viability Assays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: Europe 15-Year Perspective for Cell Viability Assays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 50: Europe Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: Europe 15-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: Europe 15-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
FRANCE
Cell Viability Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 56: France Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: France Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: France 15-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
TABLE 59: France Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: France Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: France 15-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
GERMANY
Cell Viability Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 62: Germany Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Germany Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: Germany 15-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
TABLE 65: Germany Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: Germany Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: Germany 15-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
ITALY
TABLE 68: Italy Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Italy Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: Italy 15-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
TABLE 71: Italy Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: Italy 15-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
UNITED KINGDOM
Cell Viability Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 74: UK Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: UK Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: UK 15-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
TABLE 77: UK Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: UK Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: UK 15-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: Rest of Europe Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: Rest of Europe 15-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: Rest of Europe Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: Rest of Europe 15-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Cell Viability Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Asia-Pacific Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: Asia-Pacific 15-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Asia-Pacific Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: Asia-Pacific 15-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
REST OF WORLD
TABLE 92: Rest of World Recent Past, Current & Future Analysis for Cell Viability Assays by Component - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Rest of World Historic Review for Cell Viability Assays by Component - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: Rest of World 15-Year Perspective for Cell Viability Assays by Component - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
TABLE 95: Rest of World Recent Past, Current & Future Analysis for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Rest of World Historic Review for Cell Viability Assays by End-Use - Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Rest of World 15-Year Perspective for Cell Viability Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, Hospital & Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030